NPI: 1215003348 · NAPLES, FL 34114 · General Acute Care Hospital · NPI assigned 11/28/2006
Authorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | LALOR, PAULA (DIRECTOR) |
| NPI Enumeration Date | 11/28/2006 |
Other providers sharing the same authorized official: LALOR, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 5,531 | $73K |
| 2019 | 21,746 | $358K |
| 2020 | 21,095 | $261K |
| 2021 | 34,783 | $758K |
| 2022 | 35,904 | $1.01M |
| 2023 | 11,195 | $357K |
| 2024 | 1,426 | $139K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 8,696 | 7,864 | $568K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 6,430 | 5,600 | $412K |
| 41899 | Unlisted procedure, dentoalveolar structures | 925 | 899 | $382K |
| 36415 | Collection of venous blood by venipuncture | 9,049 | 6,403 | $334K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,027 | 939 | $194K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1,003 | 892 | $168K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,936 | 2,389 | $142K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,573 | 2,138 | $134K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,475 | 1,244 | $130K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,552 | 1,401 | $94K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,425 | 2,173 | $78K |
| G0378 | Hospital observation service, per hour | 439 | 377 | $69K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 566 | 327 | $24K |
| 87400 | 770 | 721 | $20K | |
| 88300 | 577 | 562 | $16K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1,039 | 908 | $16K |
| 81025 | 2,978 | 2,697 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,255 | 1,995 | $11K |
| 87428 | 1,827 | 1,672 | $11K | |
| 99218 | 56 | 53 | $11K | |
| 80053 | Comprehensive metabolic panel | 8,088 | 6,295 | $10K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2,320 | 2,062 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8,399 | 6,616 | $9K |
| 71045 | Radiologic examination, chest; single view | 3,975 | 3,421 | $8K |
| 84484 | 3,199 | 2,108 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,373 | 3,408 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | 121 | 103 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 552 | 511 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 3,453 | 2,987 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 302 | 247 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,426 | 2,733 | $4K |
| 81001 | 3,690 | 3,225 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1,200 | 1,086 | $3K |
| J2704 | Injection, propofol, 10 mg | 1,866 | 1,692 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,958 | 1,832 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 317 | 264 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,139 | 839 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 45 | 41 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,557 | 1,182 | $2K |
| 71046 | Radiologic examination, chest; 2 views | 263 | 246 | $2K |
| 72131 | 15 | 14 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 477 | 412 | $2K |
| 82962 | 1,345 | 544 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,586 | 1,957 | $2K |
| 81003 | 1,229 | 1,108 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 456 | 427 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,311 | 1,162 | $1K |
| 94760 | 1,548 | 779 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,963 | 1,714 | $1K |
| 87430 | 365 | 343 | $1K | |
| 85610 | 2,253 | 1,880 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 48 | 40 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 178 | 112 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 831 | 788 | $1K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 149 | 25 | $960.67 |
| 83690 | 2,799 | 2,452 | $939.28 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 29 | 27 | $906.46 |
| 82550 | 525 | 450 | $897.20 | |
| 83735 | 2,570 | 1,946 | $883.76 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,232 | 979 | $810.11 |
| 87186 | 354 | 306 | $779.57 | |
| 87077 | 369 | 320 | $778.69 | |
| 84443 | Thyroid stimulating hormone (TSH) | 725 | 616 | $766.93 |
| 83880 | 729 | 612 | $761.28 | |
| 86901 | 55 | 51 | $757.32 | |
| 85027 | 796 | 550 | $701.98 | |
| 85730 | 1,746 | 1,481 | $530.85 | |
| 96376 | 134 | 77 | $477.35 | |
| 83605 | 417 | 325 | $284.97 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,629 | 993 | $266.97 |
| 94664 | 59 | 55 | $251.99 | |
| 87040 | 305 | 166 | $216.15 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 968 | 690 | $216.00 |
| 73630 | 31 | 27 | $114.99 | |
| 73562 | 17 | 14 | $109.91 | |
| 80061 | Lipid panel | 352 | 299 | $84.70 |
| 87807 | 43 | 41 | $81.95 | |
| 85379 | 312 | 277 | $75.04 | |
| 86140 | 167 | 145 | $59.61 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 26 | 24 | $27.96 |
| 83036 | Hemoglobin; glycosylated (A1C) | 130 | 107 | $19.86 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 161 | 145 | $16.67 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 161 | 145 | $8.34 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 16 | 16 | $0.00 |
| 82077 | 106 | 90 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 15 | 12 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 103 | 77 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 12 | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 25 | 24 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 12 | 12 | $0.00 |
| 84702 | 226 | 191 | $0.00 | |
| 86900 | 55 | 51 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 430 | 416 | $0.00 |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | 181 | 152 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 39 | 37 | $0.00 |
| 82248 | 12 | 12 | $0.00 | |
| 73610 | 12 | 12 | $0.00 |